Fig. 8

Caspase-3 staining in lung epithelium and neoplasia. A Bar graph of Caspase-3 LI (%) in the lung parenchyma and tumors (adenoma/carcinoma) of mice in the different groups. *: significance vs. G6 at P ≤ 0.05; **: significance vs. G2 at P ≤ 0.001; ***: significance vs. G2 at P ≤ 0.0001, ****: significant vs. G2 at P < 0.00001. B–S Photomicrographs showing Caspase-3 IHC staining patterns in different groups; B normal mouse lung epithelium from Group 1 showing low Caspase-3 IHC staining affinity; C alveolar epithelial hyperplasia from Group 2 with a marked increase of Caspase-3 immunostaining; D, E lung epithelium from Groups 3 and 4 treated with BPE and Avastin, respectively; F lung epithelium from Group 5 treated with BPENP; G lung epithelium from Group 6 treated with both BPENP and Avastin. Notice the reduced thickness of the alveolar epithelial hyperplasia after all treatments, particularly in Group 6, compared to the normal control. H Bronchioloalveolar adenoma from Group 2, I a magnified portion of G. Notice the reduced size of the adenomas after the treatment with BPE (J), Avastin (K), BPENP (L), or both (M). N Bronchioloalveolar adenocarcinomas from Group 2; O magnified portion of M. The treatment with BPE (P), Avastin (Q), BPENP (R), or both (S) reduced the adenocarcinoma sizes when compared to that in Group 2